About
XTL Biopharmaceuticals focuses on the acquisition and development of late-stage pharmaceutical product candidates for the treatment of unmet clinical needs. The company has three product candidates in clinical development. XTLs hCDR1 peptide is a compound that works via a novel mechanism for the treatment of systemic lupus erythematosus (SLE). hCDR1 has completed three clinical trials involving more than 400 patients. Recombinant erythropoietin is a compound being developed by XTL with the potential to help advanced-stage multiple myeloma patients live longer with a better quality of life. The companys SAM-101 is a proprietary combination of antipsychotic drugs and a known medicinal compound for the treatment of psychotic diseases, with a focus on schizophrenia. SAM-101 has completed a phase 2a study in accordance with the Helsinki guidelines at the Shalvata Medical Center.
Funding history · 4 rounds · $30.0M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did XTL Biopharmaceuticals go public on NASDAQ?
- XTL Biopharmaceuticals went public on NASDAQ in September 2005.
- What is hCDR1 peptide, developed by XTL Biopharmaceuticals?
- hCDR1 peptide is a compound developed by XTL Biopharmaceuticals that works via a novel mechanism for the treatment of systemic lupus erythematosus (SLE). It has completed three clinical trials involving over 400 patients.
- What is the purpose of Recombinant erythropoietin being developed by XTL Biopharmaceuticals?
- Recombinant erythropoietin is a compound being developed by XTL Biopharmaceuticals with the potential to help advanced-stage multiple myeloma patients live longer with a better quality of life.
- What is SAM-101 and what stage of development has it reached?
- SAM-101 is a proprietary combination of antipsychotic drugs and a known medicinal compound for the treatment of psychotic diseases, focusing on schizophrenia. It has completed a phase 2a study at the Shalvata Medical Center.
- When did XTL Biopharmaceuticals complete the acquisition of The Social Proxy?
- XTL Biopharmaceuticals completed the acquisition of The Social Proxy in August 2024, which also included a private placement of $1.5 million.
- What was a significant acquisition made by XTL Biopharmaceuticals in January 2026?
- In January 2026, XTL Biopharmaceuticals acquired 85% of Beyond Air’s subsidiary NeuroNOS, entering the autism market.
- What was the latest funding round for XTL Biopharmaceuticals, and when did it occur?
- The latest funding round for XTL Biopharmaceuticals was a PIPE round in August 2024, raising $1.5 million. For full financing history, refer to startupim.
- What was a notable leadership change at XTL Biopharmaceuticals in April 2025?
- In April 2025, XTL Biopharmaceuticals named Mr. Noam Band as its new Chief Executive Officer.
- What was XTL Biopharmaceuticals' acquisition target in April 2026?
- In April 2026, XTL Biopharmaceuticals announced its plan to acquire Psyga Bio, aiming to establish a psychedelic biotechnology platform.